Birgit C. Schultes
EVP, Chief Scientific Officer · Intellia Therapeutics, Inc.
- 2025
- Mar 3, 2026
- 3
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Birgit C. Schultes files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- John M. Leonard - $1.44M in NTLA purchases and sales in the last 12 months
- Fred E. Cohen - $1.40M in NTLA purchases and sales in the last 12 months
- Edward J. Dulac III - $234K in NTLA purchases and sales in the last 12 months
- James Basta - $112K in NTLA purchases and sales in the last 12 months
- David Lebwohl - $110K in NTLA purchases and sales in the last 12 months
- Eliana Clark - $96K in NTLA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Birgit C. Schultes?
Birgit C. Schultes is a corporate insider, tracked as EVP, Chief Scientific Officer of Intellia Therapeutics, Inc. (NTLA). InsiderAlpha holds 3 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Birgit C. Schultes last file a Form 4?
The most recent primary Form 4 on record is dated 3 March 2026, one of 3 filings going back to 2025.
Has Birgit C. Schultes been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($79K) across all tracked filings.
